Hamam Rimi, Ali Arwa M, Alsaleh Khalid A, Kassem Moustapha, Alfayez Musaed, Aldahmash Abdullah, Alajez Nehad M
Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia.
Medical oncology unit, Department of Medicine, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia.
Sci Rep. 2016 May 16;6:25997. doi: 10.1038/srep25997.
Breast cancer (BC) is the most common cancer type and the second cause of cancer-related death among women. Therefore, better understanding of breast cancer tumor biology and the identification of novel biomarkers is essential for the early diagnosis and for better disease stratification and management choices. Herein we developed a novel approach which relies on the isolation of circulating microRNAs through an enrichment step using speed-vacuum concentration which resulted in 5-fold increase in microRNA abundance. Global miRNA microarray expression profiling performed on individual samples from 23 BC and 9 normals identified 18 up-regulated miRNAs in BC patients (p(corr) < 0.05). Nine miRNAs (hsa-miR-4270, hsa-miR-1225-5p, hsa-miR-188-5p, hsa-miR-1202, hsa-miR-4281, hsa-miR-1207-5p, hsa-miR-642b-3p, hsa-miR-1290, and hsa-miR-3141) were subsequently validated using qRT-PCR in a cohort of 46 BC and 14 controls. The expression of those microRNAs was overall higher in patients with stage I, II, and III, compared to stage IV, with potential utilization for early detection. The expression of this microRNA panel was slightly higher in the HER2 and TN compared to patients with luminal subtype. Therefore, we developed a novel approach which led to the identification of a novel microRNA panel which was upregulated in BC patients with potential utilization in disease diagnosis and stratification.
乳腺癌（BC）是最常见的癌症类型，也是女性癌症相关死亡的第二大原因。因此，更好地了解乳腺癌肿瘤生物学并鉴定新的生物标志物对于早期诊断以及更好地进行疾病分层和管理选择至关重要。在此，我们开发了一种新方法，该方法依赖于通过使用快速真空浓缩的富集步骤来分离循环微RNA，这使得微RNA丰度增加了5倍。对来自23例乳腺癌患者和9例正常人的个体样本进行的全球miRNA微阵列表达谱分析确定了乳腺癌患者中有18种上调的miRNA（p（校正）<0.05）。随后，使用qRT-PCR在46例乳腺癌患者和14例对照的队列中对9种miRNA（hsa-miR-4270、hsa-miR-1225-5p、hsa-miR-188-5p、hsa-miR-1202、hsa-miR-4281、hsa-miR-1207-5p、hsa-miR-642b-3p、hsa-miR-1290和hsa-miR-3141）进行了验证。与IV期患者相比，这些微RNA在I期、II期和III期患者中的表达总体上更高，具有早期检测的潜在用途。与管腔亚型患者相比，该微RNA面板在HER2和TN患者中的表达略高。因此，我们开发了一种新方法，该方法导致鉴定出一种新的微RNA面板，该面板在乳腺癌患者中上调，具有疾病诊断和分层的潜在用途。
